Dietary fibre blend improves gut health in patients with irritable bowel syndrome following a low FODMAP diet: a randomised, double-blind control trial.

Eur J NutrSep 24, 2026 (epub)
Clinical ResearchGastroenterologyOpen access

Ran Yan, Amanda Devine, Johnny Lo et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized, double-blind controlled trial investigated the effects of a 3-week ur gut ® supplementation on gut health in 26 adults with irritable bowel syndrome (IBS) following a low FODMAP diet. The ur gut ® group showed a significant increase in resistant starch intake and a 5.5-fold increase in Ruminococcus E, alongside improvements in gastrointestinal-specific anxiety and quality of life.

Key findings

  • ur gut ® supplementation led to a 5.5-fold increase in Ruminococcus E (P < 0.01).
  • Participants in the ur gut ® group had lower energy intake (P < 0.05) compared to placebo.
  • GI-specific anxiety improved significantly in the ur gut ® group (P = 0.01).
  • Resistant starch intake increased significantly in the ur gut ® group (P < 0.001) compared to baseline.

Why it matters

The study highlights a potential dietary strategy to enhance gut health in IBS patients without compromising symptom control, which is crucial for managing this common gastrointestinal disorder.

Source

PubMed · PMID 42782339Free full text on PubMed Central

Published in Eur J Nutr. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.